Summit has presented new data from its Phase Ib modified diet trial of SMT C1100 in DMD and on its pre-clinical pipeline of 2nd generation compounds. Most importantly, the data confirms that a modified diet can positively impact the absorption of SMT C1100 and achieve potentially therapeutic levels. The results are highly supportive of the continued development of SMT C1100 and second-generation utrophin modulators in DMD, an ultimately fatal muscle wasting disease with no cure. We remain upbeat on Summit and look forward to the start of Phase II trials later this year.